Single-nucleotide polymorphisms of matrix metalloproteinases and their inhibitors in gastrointestinal cancer

Table 5 Polymorphisms of matrix metalloproteinases in colorectal cancer

Gene	SNP	Reference	Ethnicity	Case/control	Parameter	Results	Parameter OR	OR	95% CI	P value
MMP-1	-1607 1G/2G	Ghilardi[92]	Caucasian	60/164	Cancer risk	Increased cancer risk in 2G/2G	2G/2G vs 1G/1G + 1G/2G	2.21	1.17-4.16	0.014
					Distant metastases	Increased risk of metastases in 2G/2G	2G/2G vs 1G/1G + 1G/2G	4.73	1.46-15.26	0.008
		Zinzindohoue[99]	Caucasian	201/0	Survival	Overall survival worse in 2G/2G	2G/2G vs 1G/1G	5.4	2.0-14.7	0.001
		Hettiaratchi[96]	Australian	503/471	Cancer risk	No difference in cancer risk
					Survival	Increased survival in 2G/2G	2G/2G vs 1G/2G + 1G/1G	0.43	0.19-0.96	0.040
					Clinicopath. par.	No correlation with any clinicopath. par.
		Woo[89]	Korean	185/304	Cancer risk	Increased cancer risk in 2G/2G and G-allele	2G/2G in patients vs controls	1.8	1.23-2.64	0.044
					LN metastases	More often >10 LN in 2G/2G
		Fang[94]	Chinese	237/252	Cancer risk	No difference in cancer risk
		Xu[97]	Chinese	126/126	Cancer risk	No difference in cancer risk
					Clinicopath. par.	No correlation with any clinicopath. par.
		Przybylowska[98]	Caucasian	33/52	Cancer risk	No difference in cancer risk
		Hinoda[91]	Japanese	101/127	Cancer risk	Increased cancer risk in 2G/2G	2G/2G vs 1G/1G + 1G/2G	2.08	1.22-3.53	0.007
					Clinicopath. par.	No correlation with any clinicopath. par.
		Biondi[93]	Caucasian	63/164	Cancer risk	More 2G allele in cancer patients				< 0.08
		de Lima[95]	Brasilian	130/130	Cancer risk	No difference in cancer risk
					Distant metastases	Increased risk of metastases in 1G allele (trend)
					LN metastases	No difference in LN metastases
		Elander[90]	Caucasian	127/208	Cancer risk	Increased cancer risk in 2G allele carriers	2G allele vs 1G allele	1.41	1.02-1.96	0.037
					Clinicopath. par.	No correlation with any clinicopath. par.
		Kouhkan[88]	Iranian	150/100	Cancer risk	Increased cancer risk in 2G/2G and G-allele
					Distant metastases	Earlier metastases in 2G/2G
MMP-2	-1306 C/T	Xu[102]	Chinese	126/126	Cancer risk	Increased cancer risk in CC	CC vs CT+TT	1.96	1.06-3.64	< 0.05
					Infiltration depth	More serosa/adventitia involvement in CC	CC vs CT+TT			0.042
		Hettiaratchi[96]	Australian	503/471	Cancer risk	No difference in cancer risk
					Survival	No difference in survival
					Clinicopath. par.	No correlation with any clinicopath. par.
		Langers[105]	Caucasian	215/0	Survival	10 year survival worse in TT	CC/CT vs TT	1.4	1.02-1.91	0.038
		Ohtani[103]	Japanese	47/67	Cancer risk	No difference in cancer risk
		Elander[90]	Caucasian	127/208	Cancer risk	No difference in cancer risk
					Clinicopath. par.	No correlation with any clinicopath. par.
MMP-2	-790 T/G	Xu[104]	Chinese	126/126	Cancer risk	No difference in cancer risk
					Infiltration depth	No difference in infiltration depth
MMP-2	-955 A/C	Xu[104]	Chinese	126/126	Cancer risk	No difference in cancer risk
					Infiltration depth	No difference in infiltration depth
MMP-2	-1575 G/A	Xu[104]	Chinese	126/126	Cancer risk	Increased cancer risk in GG and G allele	GG vs GA+AA	1.96	1.06-3.64	0.04
					Infiltration depth	More serosa/adventitia infiltration in GG	GG vs GA+AA			< 0.05
MMP-3	-1171 5A/6A	Hinoda[91]	Japanese	101/127	Cancer risk	Increased cancer risk in 6A/6A	6A/6A vs 5A/5A + 5A/6A	2.11	1.17-3.82	0.01
					Clinicopath. par.	No correlation with any clinicopath. par.
		Biondi[93]	Caucasian	63/164	Cancer risk	No difference in cancer risk
		Ghilardi[92]	Caucasian	60/164	Cancer risk	No difference in cancer risk
					Distant metastases	No difference in metastases
		Woo[89]	Korean	185/304	Cancer risk	No difference in cancer risk
					LN metastases	No difference in LN metastases
		Ohtani[103]	Japanese	47/67	Cancer risk	No difference in cancer risk
		Elander[90]	Caucasian	127/208	Cancer risk	No difference in cancer risk
					Clinicopath var.	No correlation with any clinicopath. par.
		Zinzindohoue[99]	Caucasian	201/0	Survival	No difference in overall survival
		Hettiaratchi[96]	Australian	503/471	Cancer risk	No difference in cancer risk
					Survival	No difference in survival
					Clinicopath. par.	No correlation with any clinicopath. par.
		Xu[97]	Chinese	126/126	Cancer risk	No difference in cancer risk
					Clinicopath. par.	No correlation with any clinicopath. par.
MMP-7	-153 C/T	Ghilardi[111]	Caucasian	58/111	Cancer risk	Increased cancer risk in T allele carriers	T allele in patients vs controls	2.2	0.89-5.48	0.05
					Clinicopath. par.	No correlation with any clinicopath. par.
		Langers[110]	Caucasian	174/0	Survival	Better survival in CC patients	CC vs CT+TT (LR)	14		0.001
MMP-7	-181 A/G	Woo[89]	Korean	185/304	Cancer risk	No difference in cancer risk
					LN metastases	No difference in LN metastases
		Fang[94]	Chinese	237/252	Cancer risk	No difference in cancer risk
		Ghilardi[111]	Caucasian	58/111	Cancer risk	Increased cancer risk in GG	GG in patients vs controls	2.41	0.98-5.89	0.03
					Distant metastases	GG more often distant metastases	G in M+ vs M-	7.5	2.07-27.19	0.001
					LN metastases	GG more frequent LN metastases
		Ohtani[103]	Japanese	47/67	Cancer risk	No difference in cancer risk
		Langers[110]	Caucasian	174/0	Survival	No difference in survival
		de Lima[95]	Brasilian	130/130	Cancer risk	No difference in cancer risk
					Distant metastases	No difference in metastases
					LN metastases	No difference in LN metastases
MMP-9	R279Q	Woo[89]	Korean	185/304	Cancer risk	No difference in cancer risk
					LN metastases	No difference in LN metastases
		Xing[106]	Chinese	137/199	Cancer risk	No difference in cancer risk
					LN metastases	No difference in LN metastases
		Fang[94]	Chinese	237/252	Cancer incidence	Increased cancer risk in RR	RR vs QQ	2.21	1.25-3.93	0.006
MMP-9	-90(CA)n	Woo[89]	Korean	185/304	Cancer risk	No difference in cancer risk
					LN metastases	No difference in LN metastases
MMP-9	-1562 C/T	Xu[107]	Chinese	126/126	Cancer risk	No difference in cancer risk
					Infiltration depth	No difference in infiltration depth
		Woo[89]	Korean	185/304	Cancer risk	Increased cancer risk in CC patients	GG in patients vs controls	1.7	1.04-2.66	0.03
					LN metastases	No difference in LN metastases
		Xing[106]	Chinese	137/199	Cancer risk	No difference in cancer risk
					LN metastases	Increased risk of LN metastases in CT+TT	CT+TT vs CC			0.02
		Langers[105]	Caucasian	215/0	Survival	No difference in survival
		Ohtani[103]	Japanese	47/67	Cancer risk	No difference in cancer risk
		Elander[90]	Caucasian	127/208	Cancer risk	No difference in cancer risk
					Clinicopath. par.	No relationschip with clinicopath. par.
MMP-12	-82A/G	Woo[89]	Korean	185/304	Cancer risk	No difference in cancer risk
					LN metastases	No difference in LN metastases

SNP: Single nucleotide polymorphism; LN: Lymph node; Clinicopath. par.: Clinicopathological parameters; OR: Odds ratio; aOR: Adjusted odds ratio; 95% CI: 95% confidence interval.